Illumina (NASDAQ:ILMN) Issues Quarterly Earnings Results

Illumina (NASDAQ:ILMN) issued its quarterly earnings results on Thursday. The life sciences company reported $1.62 earnings per share for the quarter, topping the consensus estimate of $1.36 by $0.26, FiscalAI reports. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company’s revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company posted $1.34 EPS.

Here are the key takeaways from Illumina’s conference call:

• Strong Q3 performance and raised guidance: Rest-of-world organic revenue grew approximately 5%, operating margin reached 25%, and adjusted EPS was $1.44, ahead of expectations. Illumina raised full-year 2026 revenue guidance to $4.64–$4.66 billion and EPS guidance to $5.40–$5.45.
• Clinical demand and NovaSeq X placements remain robust: The company placed more than 80 NovaSeq X instruments in Q3, with clinical sequencing consumables growing 14% year over year. Illumina said the expanding installed base should support consumables revenue for years and expects clinical consumables growth in the mid-teens for 2026.
• Research and applied sequencing consumables declined 6% in the rest of the world, although management said activity appears to be stabilizing. The NovaSeq X transition is largely complete in research markets, while clinical conversion is expected to reach roughly 80%–85% and continue creating pricing headwinds, though less so in 2027.
• Margins and cash generation improved: Q3 gross margin was 69.4% and free cash flow was $378 million. Illumina expects approximately 23.6% operating margin for full-year 2026 and plans to continue opportunistic share repurchases, with about $1.8 billion remaining under its authorization.
• AI, multi-omics, and data initiatives are emerging growth opportunities: Illumina reported growing interest in its Billion Cell Atlas and BioInsight platform, including from GSK, and expects these offerings to become more visible in the financial results around 2027. Management believes multi-omics and AI-driven biological datasets could provide upside beyond its high-single-digit long-term growth framework, though the timing and scale remain uncertain.

Illumina Stock Down 17.6%

Shares of ILMN stock traded down $51.02 during mid-day trading on Friday, hitting $239.03. 2,376,373 shares of the stock traded hands, compared to its average volume of 2,162,610. The stock’s fifty day moving average is $248.84 and its two-hundred day moving average is $175.73. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40. Illumina has a 52-week low of $106.12 and a 52-week high of $309.35. The stock has a market cap of $36.09 billion, a P/E ratio of 44.69, a P/E/G ratio of 4.09 and a beta of 1.41.

Illumina News Roundup

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina reported third-quarter adjusted earnings of $1.44 per share, above the $1.36 analyst consensus and up from $1.34 a year earlier. Illumina Q3 Earnings Beat Estimates
• Positive Sentiment: Management raised its 2026 guidance, citing strong clinical sequencing demand and continued adoption of the NovaSeq X platform. These trends support expectations for improved growth in clinical markets, even as research-related demand remains softer. ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical Growth
• Positive Sentiment: Longer term, Illumina remains positioned in expanding genomics markets, including clinical sequencing, population screening, metagenomics and precision medicine. 3 Promising Genomics Stocks to Add to Your Portfolio Now
• Neutral Sentiment: JPMorgan reduced its price target to $300 from $320, signaling somewhat lower near-term expectations while maintaining a target above recent trading levels. JPMorgan Adjusts Price Target on Illumina
• Negative Sentiment: Third-quarter revenue increased 4.2% year over year to approximately $1.13 billion but fell short of Wall Street expectations. Investors also reacted negatively to ongoing China revenue pressures, softer research demand and pricing pressure. Illumina Shares Tumble Despite Earnings Beat on China Woes

Insider Activity at Illumina

In other Illumina news, SVP Christensen Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Keith A. Meister sold 119,501 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $218.40, for a total transaction of $26,099,018.40. Following the completion of the transaction, the director owned 770,350 shares in the company, valued at approximately $168,244,440. This trade represents a 13.43% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 2,061,235 shares of company stock valued at $436,356,102. 2.90% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Guggenheim increased their target price on shares of Illumina from $226.00 to $305.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. JPMorgan Chase & Co. increased their price objective on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Stephens lowered Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price objective for the company. in a research note on Friday, October 23rd. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Finally, Leerink Partners upped their price target on Illumina from $220.00 to $300.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 29th. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $234.41.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.